Hostname: page-component-cd9895bd7-dzt6s Total loading time: 0 Render date: 2024-12-24T19:27:28.501Z Has data issue: false hasContentIssue false

MODELING COST OF TREATMENT WITH NEW TOPICAL TREATMENTS FOR GLAUCOMA

Results from France and the United Kingdom

Published online by Cambridge University Press:  01 January 1999

Gisela Kobelt
Affiliation:
Health Dynamics International Ltd.
Linus Jönsson
Affiliation:
Stockholm Health Economics

Abstract

Several new topical agents have been introduced recently and it can be expected that the treatment of glaucoma will change, depending on how effectively these agents control intraocular pressure (IOP). IOP is considered the major risk factor in the development of glaucomatous damage. In order to estimate the impact of these new agents on the cost of treating glaucoma, a simulation model was created to estimate the cost of treating patients with a recent diagnosis of primary open-angle glaucoma or ocular hypertension in different countries. The Markov model is based on retrospective chart reviews in different countries and calculates only cost, not outcome. Results are presented for France and the United Kingdom, where current treatment appeared to be comparable. Average one-year costs per patient with current treatment were FF2,389 (US $389) and £380 (US $627), respectively. Costs with the new treatments were lower than with current therapy.

Type
GENERAL ESSAYS
Copyright
© 1999 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)